Anti-KDM3A/JMJD1A Antibody, clone F0231

Lysine-specific demethylase 3A (UniProt: Q6PCM1; also known as EC:1.14.11.65, JmjC domain-containing histone demethylation protein 2A, Jumonji domain-containing protein 1A, [histone H3]-dimethyl-L-lysine(9) demethylase 3A) is encoded by the Kdm3a (also known as Jhdm2a, Jmjd1a, Kiaa0742) gene (Gene ID: 104263) in mouse. KDM3A is a member of the Jumonji C (JmjC) domain-containing family of histone demethylases. KDM3A contains a C-terminal JmjC domain that catalyzes the demethylation of mono- and di-methylated lysine 9 on histone H3 (H3K9me1/me2), a modification associated with transcriptional repression. In addition, it contains a zinc-finger domain for DNA binding and an LXXLL motif for interacting with nuclear receptors. As a result of KDM3A demethylation of H3K9me1/me2, gene transcription increases. This enzymatic activity plays a crucial role in regulating gene expression by altering chromatin structure, thereby influencing various biological processes such as cell differentiation, proliferation, spermatogenesis, energy metabolism, stem cell regulation, and development. JMJD1A is also involved in beige adipogenesis through a multistep process where phosphorylation of S265 of JMJD1A stimulates its H3K9me2 demethylase activity that ultimately results in the thermogenic gene regulation in beige adipogenesis. KDM3A is expressed in a wide range of tissues, with particularly high levels in the testes, reflecting its role in spermatogenesis. The involvement of KDM3A in disease has been increasingly recognized, particularly in cancer, where it is often overexpressed and contributes to tumor progression by activating oncogenes and promoting cell cycle progression. Additionally, KDM3A has been implicated in metabolic disorders and cardiovascular diseases. The therapeutic potential of targeting KDM3A in disease contexts is an area of active research. (Ref.: Takahashi, H., et al. (2022). Nat Commun. 13(1);5715; Yoo, J., et al., (2020), Cancers, 12(5), 1098)

Recombinant protein corresponding to 51 amino acids from the C-terminal half of mouse KDM3A/JMJD1A.

Quality Control Testing

Evaluated by Western Blotting in NIH/3T3 cell lysate.

Western Blotting Analysis: A 1:1,000 dilution of this antibody detected KDM3A/JMJD1A in NIH/3T3 cell lysate.






Tested Applications

Western Blotting Analysis: A representative lot detected KDM3A/JMJD1A in Western Blotting application (Takahashi, H., et al. (2022). Nat Commun. 13(1);5715).

Immunoprecipitation Analysis: A representative lot immunoprecipitated KDM3A/JMJD1A in lysate from 3T3-L1 pre-adipocytes. (Takahashi, H., et al. (2022). Nat Commun. 13(1);5715).

Chromatin Immunoprecipitation (ChIP) Analysis: A representative lot detected KDM3A/JMJD1A in Chromatin Immunoprecipitation application (Takahashi, H., et al. (2022). Nat Commun. 13(1);5715).

ChIP-seq: A representative lot detected KDM3A/JMJD1A in ChIP-seq application (Takahashi, H., et al. (2022). Nat Commun. 13(1);5715).

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Clone F0231 is a mouse monoclonal antibody that detects KDM3A/JMJD1A. It targets an epitope within 51 amino acids from the C-terminal half.

Purified mouse monoclonal antibody IgG2a in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

1.0 mg/mL. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommended storage: +2°C to +8°C.

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.